Mechanism of ETI Therapy on NLRP3 Inflammasome in Cystic Fibrosis
Pubblicato da：Unknown
·Pubblicato il: 2025-12-14
Discussion regarding how elexacaftor/tezacaftor/ivacaftor (ETI) therapy functions to downregulate the NLRP3 inflammasome pathway and subsequently reduce pro-inflammatory cytokine production in the context of cystic fibrosis.
Caricamento...